Want to see IN:ASTRAZEN full AI Analyst Report?
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹7,075.00 - ₹9,850.00
Previous CloseN/A
Volume65.42K
Average Volume (3M)602.00
Market Cap
₹178.03B
Enterprise Value₹190.61K
Total Cash (Recent Filing)₹4.48B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)104.7
Beta0.65
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.51%
Share Statistics
EPS (TTM)67.85
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)22.24
Price to Sales (P/S)8.53
P/FCF Ratio6.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion indicates continued demand for the company’s prescription portfolio and provides a durable base for future growth, particularly if specialty therapies continue gaining physician and institutional adoption.
Specialty Branded PortfolioExposure to multiple specialty therapeutic areas diversifies the business and can support stronger product differentiation than commoditized medicines, while AstraZeneca’s portfolio provides an established foundation for Indian commercialization.
Conservative Balance SheetLow leverage limits solvency risk and preserves financial flexibility for continued commercial investment or future portfolio expansion. Although debt increased, the company remains conservatively financed relative to its equity base.
Bears Say
Sharp Cash Flow DeteriorationThe steep reduction in operating and free cash flow weakens internal funding capacity and raises concerns about working-capital volatility or higher cash usage. Persistent weak conversion could constrain reinvestment and shareholder returns.
Margin CompressionLower gross and operating margins indicate pressure from product mix, costs, or pricing. If sustained, profitability compression could limit the benefit of revenue growth and reduce the company’s ability to absorb competitive or regulatory pressure.
Declining EPSNegative EPS growth shows that earnings are not keeping pace with the company’s expansion. This reinforces concerns that margin pressure and weaker cash generation may be affecting underlying profitability rather than representing only top-line volatility.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹7075.00 and its highest was ₹9850.00 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹178.03B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is Nov 14, 2026 which is in 76 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on Aug 10, 2026. The company reported ₹15.172 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹36 which represents an annual dividend yield of 0.51%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹15.172 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.354%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Glenmark Pharmaceuticals Limited
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―